Which semaglutide is most effective for weight loss?

What does the clinical evidence actually say about semaglutide's effectiveness?

The headline figure most people have heard is 15%. That comes from the STEP 1 trial, published in the New England Journal of Medicine: 68 weeks, semaglutide 2.4mg weekly versus placebo, in adults with obesity but without diabetes. Participants lost an average of around 15% of their body weight, compared with around 2.4% in the placebo group. That is a meaningful difference, and it is why NICE subsequently recommended Wegovy for use in specialist weight management services.

The story did not stop there. When the MHRA approved a 7.2mg maintenance dose in January 2026 (and then a dedicated single-dose 7.2mg pen in April 2026) it did so on trial data showing approximately 20.7% average weight loss over 72 weeks. That result closes the gap considerably on the highest doses of tirzepatide, which you can read about on our semaglutide effectiveness overview. Neither figure is a promise; both are population averages from controlled conditions, and individual results vary.

A question our prescribers hear most weeks is whether someone can simply start on the highest dose to get faster results. The answer is no, and the reason is straightforward: semaglutide is titrated slowly (starting at 0.25mg weekly and escalating roughly every four weeks) to give your body time to adjust and reduce the likelihood of nausea. The titration schedule is part of how the medicine works safely, not a formality to skip. Your prescriber sets the pace based on how you are tolerating each step.

Does the form semaglutide comes in change how effective it is?

Wegovy is available as a weekly injection and, since June 2026, as a daily tablet. The tablet (a 25mg oral dose taken first thing in the morning on an empty stomach) was approved by the MHRA as the first oral GLP-1 licensed in the UK for weight management. Effectiveness data for the tablet comes from the OASIS 4 phase 3 trial: an average weight loss of around 13.6% over 64 weeks regardless of adherence, rising to approximately 17% among participants who stayed fully on schedule throughout the trial.

The injection and tablet routes work through the same mechanism (semaglutide activates GLP-1 receptors, slowing gastric emptying and reducing appetite) but the tablet's bioavailability is lower, which is why the maintenance dose is set at 25mg rather than 2.4mg. Neither route is categorically superior for every person. The injection has the longer evidence base and a slightly higher average loss in head-to-head-comparable data; the tablet removes needles entirely and requires no refrigeration, which matters to people who travel frequently or find injections difficult. The right form is a clinical and practical decision, not a marketing one. You can explore the injection option further on the Wegovy effectiveness page.

Injection site also has a small but real effect on how consistently the medicine is absorbed. Rotating between the abdomen, thigh, and upper arm is recommended; there is some evidence that certain sites produce marginally more stable absorption, which our guide to Wegovy injection sites covers in detail.

What else determines whether semaglutide works as well as the trials suggest?

Consistency is the single biggest real-world factor. Semaglutide reaches a steady state in the body after several weeks; missing doses disrupts that steady state and can cause the medicine to feel less effective or side effects to return when you restart. Some people also notice unexpected changes during treatment, and if you have experienced scalp itching while taking Wegovy, our dedicated page explains what the evidence says and when it is worth raising with your prescriber. The timing of Wegovy's effectiveness (when in the treatment course people typically notice the most change) is something people often want to know, and it is worth reading alongside this page.

Diet quality matters too, though perhaps not in the way people expect. Appetite falls noticeably on semaglutide, which makes eating less easier. What becomes important is eating enough protein and fibre within a smaller food volume, both to preserve muscle and to maintain energy. The NHS guidance on obesity treatment is clear that medicines work best alongside dietary and activity changes, not instead of them.

Underlying health factors (insulin resistance, hypothyroidism, sleep apnoea, certain medications) can all affect how someone responds to any weight-loss treatment. This is part of why a clinical assessment matters before starting. It is also why the most effective semaglutide is, in one sense, the dose and form that a prescriber has judged right for your specific picture, not the highest available dose. For a full breakdown of costs alongside clinical context, our weight-loss treatment overview is a useful place to compare options.

If you would like to find out whether Wegovy could be clinically appropriate for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, with no waiting list.